RxDoctor Payments Data

Aaron Henderson, DO

Hematology & Oncology · Eglin Afb, FLNPI 1316231129

Payments from drug & device makers

$9,417in general payments, 2019–2025

Across 508 payments — averaging $18.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bristol Myers Squibb$817
  • Novartis$799
  • Regeneron Healthcare Solutions, Inc.$605
  • Johnson & Johnson$539
  • Merck$423
  • E.r. Squibb & Sons, L.L.C.$417
  • plus $6K from 54 others

What the payments were for

  • Food & beverage$9,36299%
  • Education$541%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Bristol Myers Squibb44$817
Novartis48$799
Regeneron Healthcare Solutions, Inc.25$605
Johnson & Johnson31$539
Merck19$423
E.r. Squibb & Sons, L.L.C.19$417
AstraZeneca(2 entities)20$349
Lilly USA, LLC18$319
Amgen23$310
Sanofi12$276
Astellas Pharma US Inc20$270
Daiichi Sankyo Inc.14$253
Pfizer15$242
AbbVie14$241
Stemline Therapeutics Inc.10$211
Exelixis Inc.11$193
GSK11$190
Array Biopharma Inc9$160
Genentech USA, Inc.10$158
Ipsen Biopharmaceuticals, Inc7$141
Blueprint Medicines Corporation7$134
Takeda Pharmaceuticals U.S.A., Inc.5$131
Beone Medicines USA, Inc.6$126
Pharmacosmos Therapeutics Inc.5$119
Sumitomo Pharma America, Inc.8$117
Recordati_rare_diseases_inc.2$116
Seagen Inc.8$115
Deciphera Pharmaceuticals Inc.5$115
Boehringer Ingelheim5$107
Incyte Corporation5$97
Jazz Pharmaceuticals Inc.4$93
Pharmaessentia USA Corporation4$90
AVEO Pharmaceuticals, Inc.5$89
EMD Serono, Inc.4$72
Coherus Oncology, Inc.4$70
Mirati Therapeutics, Inc.4$57
Beigene USA, Inc.4$56
Rigel Pharmaceuticals, Inc.3$54
Eisai Inc.3$51
Tersera Therapeutics LLC2$50
Pharming Healthcare, Inc.2$41
Springworks Therapeutics, Inc.2$40
Tempus AI, Inc2$40
Sobi, Inc2$39
Celltrion USA Inc.1$38
Spectrum Pharmaceuticals Inc.2$36
Adaptive Biotechnologies Corporation2$32
Gilead2$31
Taiho Oncology, Inc.2$31
Janssen Scientific Affairs, LLC1$30
Puma Biotechnology, Inc.2$27
Myovant Sciences Inc.2$27
Genmab U.S., Inc.1$25
Syndax Pharmaceuticals, Inc.1$24
ADC Therapeutics America, Inc.1$19
Paratek Pharmaceuticals, Inc.1$19
Immunogen, Inc.1$19
Iovance Biotherapeutics, Inc.1$18
Karyopharm Therapeutics Inc.1$17
Bayer1$17

How this compares

$9,417 in reported general payments places this provider in the 45th percentile of 694 hematology & oncology providers in Florida.

See all hematology & oncology providers in Florida

Medicare billing

Part B allowed, 2024
$3,662,256
Medicare patients
449
Services billed
204,373

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CabometyxCabozantinib S-Malate11$439,723
Lenalidomide18$430,329
JakafiRuxolitinib Phosphate15$258,053
CalquenceAcalabrutinib Maleate19$227,200
XtandiEnzalutamide16$211,927
Abiraterone Acetate12$58,697
EliquisApixaban46$33,219
XareltoRivaroxaban12$11,061
OxycontinOxycodone Hcl13$4,309
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen57$1,755
Dexamethasone57$1,131
Letrozole42$821
Anastrozole43$555
Gabapentin40$476
Ondansetron OdtOndansetron31$472

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Exelixis Inc.Cabometyx$193$439,72311 claims
Incyte CorporationJakafi$97$258,05315 claims
AstraZenecaCalquence$349$227,20019 claims
Astellas Pharma US IncXtandi$270$211,92716 claims
Janssen Scientific Affairs, LLCAbiraterone Acetate$30$58,69712 claims
PfizerEliquis$242$33,21946 claims
Johnson & JohnsonXarelto$539$11,06112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 694 hematology & oncology providers in Florida.

Other hematology & oncology in Eglin Afb

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →